Kevin Kunzmann

Results from the 400,000-plus patient trial show a pulse detection app on the Apple Watch may aid users in detecting risks of atrial fibrillation.

Crizanlizumab is the first ever drug approved to reduce vaso-occlusive crises in patients with the rare blood disease.

For what other indications, and in what regimens, are investigators assessing the drug class?

The IL-5 inhibitor has shown significant benefits for HES in a phase 3 pivotal trial, and is now being considered for regulatory submission.

Certain diet-based comorbid conditions are more prevalent in food-allergic patients.

At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.

Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?

Though research behind preventive measures is lacking, there are common steps that could be taken to reduce pediatric risk.

As new methods of treatment come to the market, allergists need to ensure their patients are fully informed and able to set their own goals for care.

Listen in to the audio transcript of a policy- and public health-based discussion on mental health stigma from a panel of experts.

How the greatest use of the drug class may just come in the most severe cases.

The rate of pediatric and adolescent patients adhering to 30-day corticosteroid refill schedules increased by nearly 50 percentage points.

A new survey shows more than 60% of adult patients with peanut allergy do not feel confident in managing their condition, despite taking preventive measures.

How can physicians train parents to trust immunotherapy—an allergen exposure they were previously told to avoid?

A growing patient population and burdens of physician shortage require specialists and primary care collaborate more and more.

Assessing a food allergy patient's overall diet during immunotherapy trials could unlock understanding how the microbiome affects the allergic reaction.

The ALK-Abello expert details the positive findings from the vast, novel assessment of Ragwitek in children with ragweed allergic rhinitis with or without conjunctivitis.

New findings show Viaskin Peanut provided significant improvements to HRQL over placebo in a pair of its clinical trials.

Distinguishing biologic-eligible patients may still need further biomarker and disease severity research.

The rate of ED cases have decreased over years, yet proper patient follow-up is still lacking.

Clinicians now have 5 agents to select from—but a limited variation of action, and an even more concise patient population eligible for treatment.

What does a modern food allergy care team look like, and what are the individual roles?

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

With new immunotherapy data and emerging biologic uses, allergists need to adjust their standards for diagnosis and care in pediatric patients.

A new survey shows patients and family members prefer telemedicine physician visits as much as they do in-person appointments—or even more so than the latter.

A 20-patient survey evidences the benefit of subcutaneous immunotherapy among patients aged 9-18 years old.

New findings from the phase 3 PALISADE and ARTEMIS trials show more than half of treated patients could tolerate 1000 mg peanut protein in a post-care food challenge.

The pivotal phase 3 findings are the largest to assess a systemic pediatric atopic dermatitis treatment, to date.

After decades of development, researchers are nearing clinical trials for immune response-shifting vaccines. Will they be feasible for patients, and accepted by clinicians?

How can clinicians and policy makers collaborate to improve the standing of mental health in the US?